General Information of the Drug (ID: M6APDG03811)
Name
AG-270
Status
Phase 1
TTD Drug ID
DN62IU
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
S-adenosylmethionine synthase 2 (MAT2A)
Methyltransferase-like 16 (METTL16)
In total 1 mechanisms lead to this potential drug response
Response Summary S-adenosylmethionine synthase 2 (MAT2A) is a therapeutic target for AG-270. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of AG-270 through regulating the expression of S-adenosylmethionine synthase 2 (MAT2A). [1], [2]
References
Ref 1 Human METTL16 is a N(6)-methyladenosine (m(6)A) methyltransferase that targets pre-mRNAs and various non-coding RNAs. EMBO Rep. 2017 Nov;18(11):2004-2014. doi: 10.15252/embr.201744940. Epub 2017 Oct 19.
Ref 2 Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol. 2006 Jul;2(7):369-74. doi: 10.1038/nchembio800. Epub 2006 Jun 11.